OTCMKTS:OPHLF Ono Pharmaceutical Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ono Pharmaceutical Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $24.90 0.00 (0.00%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$24.90▼$24.9050-Day Range$24.80▼$27.0852-Week Range$20.57▼$27.08VolumeN/AAverage Volume110 shsMarket Capitalization$12.80 billionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest Ono Pharmaceutical MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish0.08% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth3.24%From $2.16 to $2.23 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.24 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Ono Pharmaceutical. Previous Next 1.0 Short Interest Percentage of Shares Shorted0.08% of the outstanding shares of Ono Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverOno Pharmaceutical has a short interest ratio ("days to cover") of 3986, which indicates bearish sentiment.Change versus previous monthShort interest in Ono Pharmaceutical has recently increased by 3.34%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOno Pharmaceutical does not currently pay a dividend.Dividend GrowthOno Pharmaceutical does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OPHLF. Previous Next 0.6 News and Social Media Coverage News SentimentOno Pharmaceutical has a news sentiment score of -0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ono Pharmaceutical insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ono Pharmaceutical are expected to grow by 3.24% in the coming year, from $2.16 to $2.23 per share.Price to Book Value per Share RatioOno Pharmaceutical has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OPHLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address About Ono Pharmaceutical (OTCMKTS:OPHLF) StockOno Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. The company offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER Capsule for improvement of the symptoms in patients with pheochromocytoma; and BRAFTOVI capsules, and MEKTOVI and VELEXBRU tablets for malignant tumors. It also provides GLACTIV and FORXIGA tablets for type 2 diabetes; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; PARSABIV, an intravenous injection for dialysis patients; ONOACT injections for tachyarrhythmia; STAYBLA tablets for overactive bladder; OPALMON tablets to treat peripheral circulatory disorder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; CORALAN for treatment of chronic heart failure; and RECALBON tablets for osteoporosis. In addition, the company is developing products for colorectal, esophageal, gastric or esophago-gastric junction, small and non-small cell lung, ovarian, pancreatic, prostate, biliary tract, hematologic, and head and neck cancers; hepatocellular, urothelial, and virus positive/negative solid carcinoma; glioblastoma; multiple myeloma; malignant pleural mesothelioma; solid tumors; central nervous system, primary testicular, and lymphoplasmacytic; acute myeloid leukemia; melanoma; primary macroglobulinemia; chronic heart failure; Parkinson's disease; structural damage of the joints in rheumatoid arthritis; polymyositis/dermatomyositis; osteoarthritis; enthesopathy; pemphigus; celebral infarction; acromegaly; thrombosis; and autoimmune disease. The company has research and collaboration agreement with Numab Therapeutics AG and Caris Life Sciences, Inc. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.Read More OPHLF Stock News HeadlinesJune 28, 2022 | seekingalpha.comFate, Ono expand team up on cancer immunotherapy programJune 10, 2022 | finance.yahoo.comOno Pharmaceutical Co. (OPHLF) Upgraded to Strong Buy: What Does It Mean for the Stock?January 7, 2022 | nasdaq.comOno Pharmaceutical Co. Ltd (OPHLF)November 13, 2021 | markets.businessinsider.comHere's what Wall Street expects from Ono Pharmaceutical's earningsJuly 28, 2021 | markets.businessinsider.comHere's what Wall Street expects from Ono Pharmaceutical's earnings reportMarch 23, 2021 | msn.comPacira (PCRX) Gets FDA Nod for Exparel in Pediatric PatientsJanuary 31, 2021 | markets.businessinsider.comHere's what to expect from Ono Pharmaceutical's earningsDecember 26, 2020 | markets.businessinsider.comNews for Ono PharmaceuticalDecember 18, 2020 | seekingalpha.comFate Therapeutics Jumped On Supportive Trial DataOctober 2, 2020 | seekingalpha.comGilead's Cancer FolliesAugust 16, 2020 | ca.finance.yahoo.comOno Pharmaceutical Co., Ltd. (OPHLF)August 2, 2020 | www.nasdaq.comOno Pharmaceutical Co Ltd (Japan) (OPHLF)September 28, 2019 | www.nasdaq.comOno Pharmaceutical Co Ltd (Japan) (OPHLF) Short InterestJuly 18, 2019 | seekingalpha.comFate Therapeutics: Updates To Thesis, Gaining Momentum In The ClinicMarch 26, 2019 | www.marketwatch.comVect-Horus enters into Collaboration and License Agreement with Ono Pharmaceutical Co., Ltd.March 18, 2019 | www.businesswire.comOno Pharmaceutical and twoXAR Announce Drug Discovery Research CollaborationSee More Headlines Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:OPHLF CUSIPN/A CIK940821 Webwww.ono.co.jp Phone(166) 263-5670Fax816-6263-2950Employees3,607Year FoundedN/ACompany Calendar Today7/05/2022Fiscal Year End3/31/2023Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio4.27 Quick Ratio3.63 Sales & Book Value Annual Sales$3.22 billion Price / Sales3.98 Cash Flow$1.70 per share Price / Cash Flow14.63 Book Value$11.45 per share Price / Book2.17Miscellaneous Outstanding Shares514,120,000Free FloatN/AMarket Cap$12.80 billion OptionableNot Optionable Beta0.38 Ono Pharmaceutical Frequently Asked Questions How has Ono Pharmaceutical's stock performed in 2022? Ono Pharmaceutical's stock was trading at $25.0350 at the start of the year. Since then, OPHLF stock has decreased by 0.5% and is now trading at $24.90. View the best growth stocks for 2022 here. Who are Ono Pharmaceutical's key executives? Ono Pharmaceutical's management team includes the following people: Mr. Gyo Sagara, CEO, Pres & Representative Director (Age 64)Mr. Shozo Matsuoka Ph.D., Corp. Exec. Officer and Exec. Director of Corp. Regulatory Compliance, Safety & QAYukio Tani, Corp. Exec. Officer & Head of Corp. CommunicationsKatsuji Teranishi, Corp. Officer and Chief Officer of Sales, Mkt, Wholesales Mgt., Planning & Primary Care Bus. Div.Mr. Isao Ono, Exec. Officer, Director of Corp. Research & Director (Age 63)Mr. Hiroshi Ichikawa, Corp. Officer & Sr. Director of Medical External AffairsMr. Toichi Takino Ph.D., Sr. Exec. Officer, Exec. Director of Discovery & Research and Director (Age 54)Mr. Toshihiro Tsujinaka, Sr. Exec. Officer, Exec. Director of Corp. Strategy & Planning and Director (Age 58)Hiromu Habashita Ph.D., Corp. Officer and Deputy Exec. Director of Discovery & Research DivisionKiyoaki Idemitsu, Exec. Officer, Exec. Director of Clinical Devel. & Director (Age 58) Who are some of Ono Pharmaceutical's key competitors? Some companies that are related to Ono Pharmaceutical include Takeda Pharmaceutical (TAK), Astellas Pharma (ALPMY), Royalty Pharma (RPRX), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), Genmab A/S (GNMSF), BeiGene (BGNE), Horizon Therapeutics Public (HZNP), Catalent (CTLT), Alnylam Pharmaceuticals (ALNY), Shiseido (SSDOY), UCB (UCBJF), BioMarin Pharmaceutical (BMRN) and Viatris (VTRS). View all of OPHLF's competitors. What is Ono Pharmaceutical's stock symbol? Ono Pharmaceutical trades on the OTCMKTS under the ticker symbol "OPHLF." How do I buy shares of Ono Pharmaceutical? Shares of OPHLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ono Pharmaceutical's stock price today? One share of OPHLF stock can currently be purchased for approximately $24.90. How much money does Ono Pharmaceutical make? Ono Pharmaceutical (OTCMKTS:OPHLF) has a market capitalization of $12.80 billion and generates $3.22 billion in revenue each year. How many employees does Ono Pharmaceutical have? Ono Pharmaceutical employs 3,607 workers across the globe. How can I contact Ono Pharmaceutical? Ono Pharmaceutical's mailing address is 8-2 Kyutaromachi 1-chome Chuo-ku, Osaka M0, 541-8564. The official website for Ono Pharmaceutical is www.ono.co.jp. The company can be reached via phone at (166) 263-5670 or via fax at 816-6263-2950. This page (OTCMKTS:OPHLF) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
